06 June 2016 | News | By BioSpectrum Bureau
ULURU inks pact with Japanese medical firm
Texas-headquartered ULURU Inc has expanded its distribution network by entering into a cooperation agreement with Saraya Co Ltd for the registration of Altrazeal and further cooperation in Japan.
Saraya is a globally located Japanese company engaged in the development, manufacture, distribution, and sales of a variety of human health, sanitation, hygiene products, and related equipment.
ULURU specializes in the development and commercialization of a portfolio of wound care and wound management products utilizing its innovative Nanoflex Aggregate technology, and mucoadhesive drug delivery film products to provide improved clinical outcomes through controlled delivery of active molecules utilizing its OraDisc transmucosal delivery system.
"Saraya is a great partner for the registration of our product Altrazeal in Japan," commented Helmut Kerschbaumer, Uluru's interim Chief Executive Officer. "Saraya has an excellent market reputation and a large sales force focused on the medical community."
Product registration will commence immediately and the company is hopeful that the registration process will be completed by year-end 2017 although regulatory approval can be unpredictable.
Kerschbaumer further said, "The commencement of registration of Altrazeal in Japan now brings the total number of markets in the process of registration to 38, which includes certain countries in Asia, the Middle East, and Latin America. This, coincidentally, is also the number of markets in which Altrazeal is already registered, including the United States and countries throughout the European Union."